A Mycobacterium tuberculosis-derived lipid inhibits membrane fusion by modulating lipid membrane domains.
Tuberculosis is an infectious and potentially fatal disease caused by the acid-fast bacillus Mycobacterium tuberculosis (MTB). One hallmark of a tuberculosis infection is the ability of the bacterium to subvert the normal macrophage defense mechanism of the host immune response. Lipoarabinomannan (LAM), an integral component of the MTB cell wall, is released when MTBs are taken into phagosomes and has been reported to be involved in the inhibition of phago-lysosomal (P-L) fusion. However, the physical chemistry of the effects of LAM on lipid membrane structure relative to P-L fusion has not been studied. We produced membranes in vitro composed of dioleoylphosphatidylcholine, sphingomyelin, and cholesterol to simulate phagosomal lipid membranes and quantified the effects of the addition of LAM to these membranes, using fluorescence resonance energy transfer assays and atomic force microscopy. We found that LAM inhibits vesicle fusion and markedly alters lipid membrane domain morphology and sphingomyelin-chollesterol/dioleoylphosphatidylcholine ratios. These data demonstrate that LAM induces a dramatic reorganization of lipid membranes in vitro and clarifies the role of LAM in the inhibition of P-L fusion and the survival of the MTB within the macrophage.
Hayakawa
Eri
E
Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, 4-1-8, Honcho, Kawaguchi, Saitama, 332-0012, Japan.
Tokumasu
Fuyuki
F
Nardone
Glenn A
GA
Jin
Albert J
AJ
Hackley
Vince A
VA
Dvorak
James A
JA
D008051:Lipid Bilayers / Q000737:chemistry*; D008070:Lipopolysaccharides / Q000737:chemistry*; D008560:Membrane Fluidity; D008561:Membrane Fusion; D021962:Membrane Microdomains / Q000737:chemistry*; D008968:Molecular Conformation; D009169:Mycobacterium tuberculosis / Q000737:chemistry*
D008051:Lipid Bilayers; D008070:Lipopolysaccharides; C050016:lipoarabinomannan
Ultramicroscopy. 2004 Aug;100(3-4):135-43
15231303
Science. 2000 Jun 2;288(5471):1647-50
10834844
Biopolymers. 1967 Feb;5(2):135-48
6040712
Biochim Biophys Acta. 1970 Jun 9;210(1):116-26
4989541
Proc Natl Acad Sci U S A. 1976 Jul;73(7):2510-4
821057
Inflammation. 1977 Jun;2(2):83-91
617805
J Biol Chem. 1986 Sep 15;261(26):12345-51
3091602
J Immunol. 1988 Jan 15;140(2):634-40
2826597
J Immunol. 1994 Sep 15;153(6):2568-78
8077667
Annu Rev Biochem. 1995;64:29-63
7574484
Science. 1995 Oct 27;270(5236):610-4
7570018
J Immunol. 1996 Jun 1;156(11):4377-83
8666810
Chem Phys Lipids. 1996 Jul 15;81(2):203-13
8810049
J Biol Chem. 2001 Jan 5;276(1):329-33
11020382
Glycoconj J. 2000 Mar-Apr;17(3 -4):199-204
11201791
Traffic. 2000 Mar;1(3):235-47
11208107
Biochemistry. 2001 Jul 27;40(28):8292-9
11444975
Adv Drug Deliv Rev. 2001 Jul 28;49(3):301-15
11551401
Biophys J. 2003 Apr;84(4):2609-18
12668469
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5437-42
12702770
Ultramicroscopy. 2003 Oct-Nov;97(1-4):217-27
12801674
FEBS Lett. 2003 Jul 17;547(1-3):101-6
12860394
Infect Immun. 2003 Aug;71(8):4684-90
12874349
J Exp Med. 2003 Aug 18;198(4):653-9
12925680
J Cell Biol. 2003 Nov 24;163(4):879-88
14623870
Biochem Biophys Res Commun. 1996 Sep 24;226(3):645-9
8831670
Cell. 1998 Mar 20;92(6):759-72
9529252
Eur Biophys J. 1999;28(3):187-99
10192934
Cell. 1999 May 14;97(4):435-47
10338208
FEMS Immunol Med Microbiol. 1999 May;24(1):11-7
10340707
Scand J Immunol. 2004 Nov;60(5):463-70
15541038
J Mol Biol. 2004 Dec 3;344(4):907-18
15544801
Cell Mol Life Sci. 2005 Jan;62(2):179-87
15666089
Acta Med Croatica. 2004;58(4):323-8
15700689
Biophys J. 2005 Feb;88(2):1120-33
15542550
J Exp Med. 2005 Oct 3;202(7):987-99
16203868
Biophys J. 2006 Mar 1;90(5):1661-75
16339880
Methods Enzymol. 2003;372:300-19
14610820
Appl Biochem Biotechnol. 2004 Jul-Sep;118(1-3):253-67
15304754